Serum Acetaminophen-Cystein (APAP-CYS) Adduct Concentrations in Subjects Expected to Develop Aminotransferase Elevations with Liver-Directed Therapy Intended to Treat Hepatic Tumors
To describe serum acetaminophen-cysteine adduct (an experimental biomarker of acetaminophen exposure) concentrations following hepatic embolization in patients taking therapeutic doses of acetaminophen three days before the procedure
This Study is
No Longer Enrolling
This study aims to describe protein adduct (an experimental biomarker of acetaminophen exposure) concentrations in patients taking therapeutic doses of acetaminophen who develop a liver injury from a cause other than acetaminophen.
Adult
Adult patients undergoing portal vein or bland embolization for the treatment of metastatic liver tumor; no known hypersensitivity or allergy to acetaminophen
Patients are not eligible with: known cirrhosis; history of moderate to severe anemia; currently taking warfarin, isoniazid, and disulfiram; weigh less than or equal to 50kg, pregnant or breastfeeding, and currently enrolled in a clinical trial
Basic Science
Local
CTRC Inpatient
Denver Health and Hospital Authority
Outpatient CTRC
University of Colorado Hospital
Protocol Number: 16-0031
More information available at ClinicalTrials.gov: NCT02911961
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers